Bionano Genomics, Inc. (LON:0A4K)

London flag London · Delayed Price · Currency is GBP · Price in USD
5.26
-0.33 (-5.82%)
At close: Jan 31, 2025
Market Cap9.59M +5.3%
Revenue (ttm)21.76M +1.0%
Net Income-23.93M
EPS-3.19
Shares Out n/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume4,768
Open5.70
Previous Close5.58
Day's Range5.19 - 5.88
52-Week Range5.00 - 80.86
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateAug 12, 2026

About Bionano Genomics

Bionano Genomics, Inc., together with its subsidiaries, provides genome analysis solutions in the Americas, Europe, the Middle East, Africa, China, Japan, South Korea, Singapore, India, and Australia. The company offers genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It also provides Saphyr and Stratys systems, which are sample-to-result solutions for structural variation analysis by ... [Read more]

Industry Surgical and Medical Instruments and Apparatus
Founded 2003
Employees 97
Stock Exchange London Stock Exchange
Ticker Symbol 0A4K

Financial Performance

In 2025, Bionano Genomics's revenue was $28.51 million, a decrease of -7.37% compared to the previous year's $30.78 million. Losses were -$26.40 million, -76.44% less than in 2024.

Financial numbers in USD Financial Statements

News

Bionano Announces Multiple Publications in 2026 Describing Unique Utility of OGM in Studies of Reproductive Health and Prenatal Genetic Disorders

SAN DIEGO, June 11, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced that to date in 2026, a total of 13 studies analyzing 730 samples were published with key findings that dem...

2 days ago - GlobeNewsWire

Bionano Announces Full Retirement of Outstanding Senior Secured Convertible Debentures

SAN DIEGO, May 28, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it has fully retired and cancelled all outstanding Senior Secured Convertible Debentures (the "De...

16 days ago - GlobeNewsWire

Bionano Genomics announces OGM study of T-cell acute lymphoblastic leukemia

Bionano Genomics (BNGO) announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping, OGM, detected genomic abnormalities in 97.8% of T-cell acute lymphoblast...

18 days ago - TheFly

Bionano Announces Largest OGM Study of T-Cell Acute Lymphoblastic Leukemia

SAN DIEGO, May 26, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced publication of a peer-reviewed study in Modern Pathology showing that optical genome mapping (OGM) det...

18 days ago - GlobeNewsWire

Bionano Genomics Earnings Call Transcript: Q1 2026

Q1 2026 revenue grew 4% year-over-year to $6.7 million, with strong consumable sales and improved gross margin. Major reimbursement wins, increased publications, and debt retirement support a positive outlook, with full-year revenue guidance reaffirmed at $30–33 million.

4 weeks ago - Transcripts

Bionano Genomics Earnings release: Q1 2026

Bionano Genomics released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.

4 weeks ago - Filings

Bionano Genomics Quarterly report: Q1 2026

Bionano Genomics has published its Q1 2026 quarterly earnings report on May 13, 2026.

4 weeks ago - Filings

Bionano Genomics Slides: Q1 2026

Bionano Genomics has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 13, 2026.

4 weeks ago - Filings

Bionano Reports First Quarter 2026 Results and Provides a Business Update

SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today reported financial results for the first quarter ended March 31, 2026. "The Bionano business is healthy, with fi...

4 weeks ago - GlobeNewsWire

Bionano Genomics files $400M mixed securities shelf

16:04 EDT Bionano Genomics (BNGO) files $400M mixed securities shelf

5 weeks ago - TheFly

Bionano Genomics Registration statement: Registration filing

Bionano Genomics filed a registration statement on May 8, 2026, providing details about a securities offering with the SEC.

5 weeks ago - Filings

Bionano Genomics CEO Erik Holmlin to step down, Al Luderer to succeed

Bionano Genomics (BNGO) announced that Al Luderer, chairman of Bionano’s board of directors, has been appointed interim president and chief executive officer, effective May 5. Luderer will continue to...

5 weeks ago - TheFly

Bionano Announces Leadership Transition

SAN DIEGO, May 06, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that Al Luderer, Ph.D., chairman of Bionano's Board of Directors, has been appointed interim president...

5 weeks ago - GlobeNewsWire

Bionano Announces a 56% Increase in Publications Describing the Utility of OGM in Rare Diseases in Q1 2026 vs Q1 2025

Overall, studies show: OGM Can Resolve Previously Unresolved Rare Disease Cases OGM Can Serve as a Gold Standard Technique for Characterization of SVs OGM Can Complement Sequencing for Better SV Sensi...

5 weeks ago - GlobeNewsWire

Bionano to Report First Quarter 2026 Financial Results and Host a Conference Call Webcast on May 13, 2026

SAN DIEGO, April 29, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced that it will host a conference call and live webcast on Wednesday, May 13, 2026, at 4:30 p.m. Easter...

6 weeks ago - GlobeNewsWire

Bionano Genomics price target lowered to $6 from $7 at H.C. Wainwright

H.C. Wainwright lowered the firm’s price target on Bionano Genomics (BNGO) to $6 from $7 and keeps a Buy rating on the shares. The firm cites the company’s increased share…

2 months ago - TheFly

Bionano Announces Publication from Johns Hopkins and MD Anderson Showing that OGM can Outperform Traditional Methods in Analysis of Multiple Myeloma

SAN DIEGO, April 02, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) announced the publication of a study in the American Journal of Hematology demonstrating that optical genome mapping...

2 months ago - GlobeNewsWire

Bionano Genomics Proxy statement: Proxy filing

Bionano Genomics filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.

2 months ago - Filings

Bionano Genomics Proxy statement: Proxy filing

Bionano Genomics filed a proxy statement on April 2, 2026, providing details for shareholder voting and corporate governance matters.

2 months ago - Filings

Bionano Genomics Earnings Call Transcript: Q4 2025

Q4 and full year 2025 revenue declined year-over-year, but gross margin and operating efficiency improved significantly. Strategic focus on high-volume routine users and software integration drove more predictable, profitable revenue, with 2026 guidance projecting 5%-16% growth.

2 months ago - Transcripts

Bionano Genomics Annual report: Q4 2025

Bionano Genomics has published its Q4 2025 annual report on March 23, 2026.

2 months ago - Filings

Bionano Genomics Earnings release: Q4 2025

Bionano Genomics released its Q4 2025 earnings on March 23, 2026, summarizing the period's financial results.

2 months ago - Filings

Bionano Genomics Slides: Q4 2025

Bionano Genomics has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 23, 2026.

2 months ago - Filings

Bionano Genomics reports Q4 revenue $7.95M vs. $8.16M last year

“2025 demonstrated the momentum we built as a business,” commented Erik Holmlin, president and CEO of Bionano. “Our routine users of optical genome mapping and VIA software remain the foundation…

2 months ago - TheFly

Bionano Genomics sees Q1 revenue $6.5M-$6.7M

Sees FY26 revenue $30M-$33M.

2 months ago - TheFly